BioLife Solutions Enters Multi-Year Supply Agreement with Qkine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
BioLife Solutions has entered into a multi-year supply agreement with Qkine under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing. The agreement provides BioLife with exclusive worldwide distribution rights to specific Qkine products for the CGT market and non-exclusive rights to Qkine products in the CGT market. In addition, the companies intend to collaborate on a process development and validation program to enable Qkine to package certain of its products using BioLife's proprietary CellSeal Connect vial system, which is designed to be incorporated into closed system and/or automated CGT workflows. Cytokines and growth factors play a vital role in the manufacturing of cell and gene therapies by regulating and stimulating cell growth, activation and performance. According to third-party market research, the current global cytokines market is estimated at $500M annually and is projected to grow at a mid-teens compound annual rate, reaching $1B by 2030, driven by expanding CGT development pipelines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLFS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLFS
Wall Street analysts forecast BLFS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.600
Low
32.00
Averages
33.25
High
34.00
Current: 26.600
Low
32.00
Averages
33.25
High
34.00
About BLFS
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surge in Options Trading Volume for CloudFlare and AMC
- CloudFlare Options Volume: CloudFlare Inc (Ticker: NET) has seen an options trading volume of 69,706 contracts today, representing approximately 7 million underlying shares, which is 137.9% of its average daily trading volume, indicating strong market interest in its future performance.
- High Strike Option Activity: Within CloudFlare, the $350 strike call option is particularly active, with 7,037 contracts traded today, representing about 703,700 shares, reflecting investor expectations for future price increases.
- AMC Options Trading Overview: AMC Entertainment Holdings Inc (Ticker: AMC) has recorded an options trading volume of 356,582 contracts today, equating to approximately 35.7 million underlying shares, or 133.1% of its average daily trading volume, showcasing heightened market interest in its stock.
- AMC High Strike Option Activity: For AMC, the $2 strike call option has seen significant activity, with 120,797 contracts traded today, representing around 12.1 million shares, indicating optimistic sentiment among investors regarding its future performance.
See More
BioLife Solutions Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BioLife Solutions reported Q1 2026 revenue of $27.5 million, reflecting a 25% year-over-year increase, indicating strong demand in the biopharmaceutical market, with full-year revenue guidance set between $112.5 million and $115 million, representing a growth of 17% to 20%.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $6.2 million in Q1, accounting for 22% of revenue, although gross margin declined due to bag yield dynamics; management remains optimistic about future profitability, viewing this decline as temporary.
- Stable Market Share: BPM products constitute over 85% of total revenue, with more than 70% market share in U.S. CGT clinical trials, underscoring the company's leadership position and sustained competitive advantage in the sector.
- Cash Flow Status: As of March 31, 2026, the company's cash and marketable securities balance was $111.5 million, down from $120.2 million as of December 31, 2025, primarily due to tax obligations and debt repayments, with management anticipating positive GAAP net income in 2026.
See More
BioLife Solutions Q1 Earnings Beat Expectations
- Strong Earnings Report: BioLife Solutions reported Q1 GAAP EPS of $0.02, beating expectations by $0.01, indicating the company's stable profitability amidst market fluctuations.
- Revenue Growth: The company achieved Q1 revenue of $27.5 million, reflecting a 15.1% year-over-year increase and surpassing market expectations by $1.84 million, showcasing its robust performance in the biopharmaceutical sector.
- 2026 Financial Guidance: BioLife reiterated its 2026 financial guidance, projecting revenue between $112.5 million and $115 million, representing a growth of 17% to 20% compared to 2025, demonstrating confidence in future expansion.
- Margin Outlook: The company anticipates GAAP and adjusted gross margins to remain in the mid-60% range, indicating ongoing improvements in cost management and profitability strategies.
See More
BioLife Solutions Reports Strong Q4 2025 Earnings Growth and Strategic Developments
- Significant Revenue Growth: BioLife Solutions reported total revenue of $96 million for 2025, reflecting a 29% year-over-year increase that exceeded expectations, driven by strong demand in the biopreservation market, particularly from commercial customers contributing nearly 50% of revenue.
- Improved Profitability: Q4 revenue reached $24.8 million, a 20% increase year-over-year, with adjusted EBITDA of $6.9 million, representing 28% of revenue, indicating ongoing enhancements in operational efficiency and profitability.
- Strategic Partnership Agreement: The company established a new distribution and product development agreement with QKine Limited for cytokines, which not only strengthens BioLife's product portfolio but also demonstrates its commitment to growth through strategic collaborations and acquisitions.
- Optimistic 2026 Outlook: Management anticipates total revenue for 2026 to be between $112 million and $115 million, representing a growth rate of 17% to 20%, and expects to achieve GAAP net income for the first time, highlighting strong prospects driven by commercial customer demand and new product initiatives.
See More
BioLife (BLFS) Q4 2025 Earnings Call Transcript
See More
BioLife Solutions Set to Announce Q4 Earnings
- Earnings Announcement Date: BioLife Solutions is scheduled to release its Q4 earnings on February 26 after market close, with investors keenly awaiting the results to assess the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $0.01, reflecting a substantial year-over-year increase of 125%, indicating a significant improvement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $24.01 million, representing a 5.8% year-over-year growth, which highlights the company's stable growth in the bioproducts market and enhances its competitive position.
- Analyst Ratings: Seeking Alpha's Quant Rating on BioLife Solutions will provide investors with additional insights for decision-making, helping them better understand the company's financial health and future direction.
See More
Surge in Options Trading Volume for CloudFlare and AMC
- CloudFlare Options Volume: CloudFlare Inc (Ticker: NET) has seen an options trading volume of 69,706 contracts today, representing approximately 7 million underlying shares, which is 137.9% of its average daily trading volume, indicating strong market interest in its future performance.
- High Strike Option Activity: Within CloudFlare, the $350 strike call option is particularly active, with 7,037 contracts traded today, representing about 703,700 shares, reflecting investor expectations for future price increases.
- AMC Options Trading Overview: AMC Entertainment Holdings Inc (Ticker: AMC) has recorded an options trading volume of 356,582 contracts today, equating to approximately 35.7 million underlying shares, or 133.1% of its average daily trading volume, showcasing heightened market interest in its stock.
- AMC High Strike Option Activity: For AMC, the $2 strike call option has seen significant activity, with 120,797 contracts traded today, representing around 12.1 million shares, indicating optimistic sentiment among investors regarding its future performance.
See More
BioLife Solutions Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BioLife Solutions reported Q1 2026 revenue of $27.5 million, reflecting a 25% year-over-year increase, indicating strong demand in the biopharmaceutical market, with full-year revenue guidance set between $112.5 million and $115 million, representing a growth of 17% to 20%.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $6.2 million in Q1, accounting for 22% of revenue, although gross margin declined due to bag yield dynamics; management remains optimistic about future profitability, viewing this decline as temporary.
- Stable Market Share: BPM products constitute over 85% of total revenue, with more than 70% market share in U.S. CGT clinical trials, underscoring the company's leadership position and sustained competitive advantage in the sector.
- Cash Flow Status: As of March 31, 2026, the company's cash and marketable securities balance was $111.5 million, down from $120.2 million as of December 31, 2025, primarily due to tax obligations and debt repayments, with management anticipating positive GAAP net income in 2026.
See More
BioLife Solutions Q1 Earnings Beat Expectations
- Strong Earnings Report: BioLife Solutions reported Q1 GAAP EPS of $0.02, beating expectations by $0.01, indicating the company's stable profitability amidst market fluctuations.
- Revenue Growth: The company achieved Q1 revenue of $27.5 million, reflecting a 15.1% year-over-year increase and surpassing market expectations by $1.84 million, showcasing its robust performance in the biopharmaceutical sector.
- 2026 Financial Guidance: BioLife reiterated its 2026 financial guidance, projecting revenue between $112.5 million and $115 million, representing a growth of 17% to 20% compared to 2025, demonstrating confidence in future expansion.
- Margin Outlook: The company anticipates GAAP and adjusted gross margins to remain in the mid-60% range, indicating ongoing improvements in cost management and profitability strategies.
See More
BioLife Solutions Reports Strong Q4 2025 Earnings Growth and Strategic Developments
- Significant Revenue Growth: BioLife Solutions reported total revenue of $96 million for 2025, reflecting a 29% year-over-year increase that exceeded expectations, driven by strong demand in the biopreservation market, particularly from commercial customers contributing nearly 50% of revenue.
- Improved Profitability: Q4 revenue reached $24.8 million, a 20% increase year-over-year, with adjusted EBITDA of $6.9 million, representing 28% of revenue, indicating ongoing enhancements in operational efficiency and profitability.
- Strategic Partnership Agreement: The company established a new distribution and product development agreement with QKine Limited for cytokines, which not only strengthens BioLife's product portfolio but also demonstrates its commitment to growth through strategic collaborations and acquisitions.
- Optimistic 2026 Outlook: Management anticipates total revenue for 2026 to be between $112 million and $115 million, representing a growth rate of 17% to 20%, and expects to achieve GAAP net income for the first time, highlighting strong prospects driven by commercial customer demand and new product initiatives.
See More
BioLife (BLFS) Q4 2025 Earnings Call Transcript
See More
BioLife Solutions Set to Announce Q4 Earnings
- Earnings Announcement Date: BioLife Solutions is scheduled to release its Q4 earnings on February 26 after market close, with investors keenly awaiting the results to assess the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $0.01, reflecting a substantial year-over-year increase of 125%, indicating a significant improvement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $24.01 million, representing a 5.8% year-over-year growth, which highlights the company's stable growth in the bioproducts market and enhances its competitive position.
- Analyst Ratings: Seeking Alpha's Quant Rating on BioLife Solutions will provide investors with additional insights for decision-making, helping them better understand the company's financial health and future direction.
See More
